Wall Street brokerages expect that Cara Therapeutics Inc (NASDAQ:CARA) will post $5.14 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Cara Therapeutics’ earnings. The lowest sales estimate is $5.00 million and the highest is $5.30 million. Cara Therapeutics posted sales of $2.87 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 79.1%. The company is expected to issue its next earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Cara Therapeutics will report full-year sales of $17.54 million for the current fiscal year, with estimates ranging from $4.38 million to $22.88 million. For the next year, analysts anticipate that the company will post sales of $22.38 million, with estimates ranging from $18.32 million to $30.30 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Cara Therapeutics.

Cara Therapeutics (NASDAQ:CARA) last issued its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.01). The firm had revenue of $4.38 million during the quarter, compared to the consensus estimate of $5.14 million. Cara Therapeutics had a negative net margin of 443.71% and a negative return on equity of 67.30%.

Several analysts have issued reports on the company. BidaskClub lowered Weyco Group from a “sell” rating to a “strong sell” rating in a research note on Saturday. HC Wainwright boosted their target price on Cara Therapeutics from $26.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, May 29th. Laidlaw boosted their price objective on Cara Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, May 29th. Needham & Company LLC boosted their price objective on Cara Therapeutics from $28.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, May 29th. Finally, Zacks Investment Research upgraded DLH from a “sell” rating to a “hold” rating in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $25.31.

Shares of CARA traded up $1.57 during mid-day trading on Friday, hitting $24.28. The stock had a trading volume of 1,122,189 shares, compared to its average volume of 536,597. The company has a market capitalization of $902.76 million, a price-to-earnings ratio of -11.79 and a beta of 2.25. The stock’s fifty day moving average price is $20.51. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.40 and a current ratio of 3.40. Cara Therapeutics has a 52 week low of $12.19 and a 52 week high of $24.37.

In other news, CFO Mani Mohindru sold 2,496 shares of the company’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $21.39, for a total value of $53,389.44. Following the completion of the transaction, the chief financial officer now directly owns 16,359 shares in the company, valued at approximately $349,919.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Frederique Ph.D. Menzaghi sold 20,000 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $21.90, for a total value of $438,000.00. Following the completion of the transaction, the insider now owns 128,882 shares of the company’s stock, valued at $2,822,515.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 41,921 shares of company stock valued at $905,677. 5.80% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the company. Deutsche Bank AG boosted its holdings in shares of Cara Therapeutics by 141.9% in the 4th quarter. Deutsche Bank AG now owns 304,177 shares of the biopharmaceutical company’s stock worth $3,953,000 after purchasing an additional 178,414 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Cara Therapeutics by 56.9% in the 4th quarter. Rhumbline Advisers now owns 44,072 shares of the biopharmaceutical company’s stock worth $573,000 after purchasing an additional 15,984 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Cara Therapeutics by 5.9% in the 4th quarter. Geode Capital Management LLC now owns 368,306 shares of the biopharmaceutical company’s stock worth $4,787,000 after purchasing an additional 20,647 shares in the last quarter. California Public Employees Retirement System boosted its holdings in shares of Cara Therapeutics by 1.4% in the 4th quarter. California Public Employees Retirement System now owns 86,798 shares of the biopharmaceutical company’s stock worth $1,128,000 after purchasing an additional 1,198 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in shares of Cara Therapeutics by 2.0% in the 4th quarter. New York State Common Retirement Fund now owns 30,700 shares of the biopharmaceutical company’s stock worth $399,000 after purchasing an additional 600 shares in the last quarter. Hedge funds and other institutional investors own 56.10% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Recommended Story: Why are gap-down stocks important?

Get a free copy of the Zacks research report on Cara Therapeutics (CARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.